Strategy Asset Managers LLC Gilead Sciences, Inc. Transaction History

Strategy Asset Managers LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 02, 2024	BUY	$63.15 - $72.88 $596,830 - $688,788	9,451 New	9,451 $648,000
Q4 2023 Feb 12, 2024	SELL	$73.27 - $83.09 $73,196 - $83,006	-999 Reduced 15.12%	5,608 $454,000
Q3 2023 Nov 09, 2023	SELL	$73.94 - $80.67 $210,285 - $229,425	-2,844 Reduced 30.09%	6,607 $495,000
Q2 2023 Aug 24, 2023	BUY	$76.01 - $86.7 $20,826 - $23,755	274 Added 2.99%	9,451 $728,000
Q1 2023 May 02, 2023	BUY	$77.31 - $88.08 $709,473 - $808,310	9,177 New	9,177 $761,000

1,927

994M

10.5M

9.75M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $116B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Strategy Asset Managers LLC, based on Form 13F filings with the SEC.

Stay updated on Strategy Asset Managers LLC with notifications on news.